PipelineNeurolixis is building a drug discovery and development pipeline:
Development of early-stage clinical assets:
Neurolixis is developing clinical-stage drugs targeted at serious CNS diseases with unmet medical needs and sizeable market opportunity.
Synthesis and development of Novel Chemical Entities (NCEs):
Neurolixis' is exploring validated, but underexploited, pharmacological targets for NCEs, including serotonin and glutamate receptors. New mechanisms of action will be favored, with a focus on "biased agonism".
All drugs or therapies will be subjected to rigorous testing under applicable law and approval by regulatory authorities, including the FDA, prior to marketing and sale.